Trial Profile
A Phase III Randomized, Double-Blind Study Of SU011248 (Sunitinib, SUTENT), A Oral Novel Multitargeted Tyrosine Kinase Inhibitor, Given Daily As A Continuous Dose Versus Placebo In Patients With Advanced/Metastatic Neuroendocrine Tumours Of The Digestive Tract
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 23 Apr 2023 Results pooled analysis from SU11248, SUN1111), Pazopanib (PAZONET), sorafenib-bevacizumab (GETNE0801) and Lenvatinib (TALENT) published in the European Journal of Cancer
- 08 Apr 2022 This trial has been completed in Spain (End Date: 15 Apr 2009), according to European Clinical Trials Database record.
- 01 Apr 2022 This trial has been completed in France (End Date: 15 Apr 2009), according to European Clinical Trials Database record.